Wild-type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells

Journal of Investigative Dermatology

Volumn 114, Issue 6, 2000, Pages 1188-1194

  Toschi, Elena ^b   Rota, Rossella ^b   Antonini, Annalisa ^a   Melillo, Guido ^a   Capogrossi, Maurizio C ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b NONE

Author keywords

Gene therapy; Recombinant adenovirus; Tumor invasiveness; Tumor suppressor genes

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0042596102     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00000.x     Document Type: Article

References (58)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, Mcewan RNA: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245, 1987
2. Albino AP, Vidai MJ, Mcnutt NS, et al: Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4:35-45, 1994
3. Bafetti LM, Young TN, Itoh Y, Stack MS: Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol Chem 273:142-149, 1998
4. Baker SJ, Fearon ER, Nigro JM, et al: Chromosome 17 deletions and p53 mutations in colorectal carcinomas. Science 244:217-221, 1989
5. Bian J, Sun Y: Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17:6330-6338, 1997
6. Blagoskolonny MV: Loss of finition and p53 protein stabilization. Oncogene 15:1889-1893, 1997
7. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
8. Cirielli C, Riccioni T, Yang C, et al: Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int J Cancer 63:1-7, 1995
9. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinomas. Cancer Res 55:1-6, 1995
10. Clayman GL, El-Naggar AK, Lippman SM, et al: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:2221-2232, 1998
11. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584, 1994
12. Demierre MF, Koh HK: Adjuvant therapy for cutaneous malignant melanoma. J Am Acad Dermatol 36:747-764, 1997
13. Donehower LA: The p53-defident mouse: a model for basic and applied cancer studies. Semin Cancer Biol 7:269-278, 1996
14. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA: A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 53:4129-4133, 1993
15. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay Y, Grimm EA, Roth JA: Therapeutic effect of retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86:1458-1462, 1994
16. Gomez-Manzano C, Fuevo J, Kyristis AP, McDonnell AP, Steck PA, Levin VA, Yung WKA: Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89:1036-1044, 1997
17. Graham FL, Prevec L: Methods for construction of adenovirus vectors. Mol Biotechnol 3:207-220, 1995
18. Halaban R: Growth factors and melanomas. Semin Oncol 23:673-681, 1996
19. Harris MP, Sutjipto S, Wills KN, et al: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 3:121-130, 1995
20. Hartmann A, Blaszyk H, Cunningham JS, et al: Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer 67:313-317, 1996
21. Hendrix MJ, Seftor EA, Chu YW, et al: Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J Natl Cancer Inst 84:165-174, 1992
22. Hujanen ES, Vaisanen A, Zheng A, Tryggvason K, Turpeenniemi-Hujanen T: Modulation of M (r) 72,000 and M (r) 92, 000 type IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int J Cancer 58:582-586, 1994
23. Kastan MB, Zhan O, El-Deiry WS, et al: Participation of p53 protein in the cellular response to DNA damage. Cell 71:587-597, 1992
24. Kleiner DE, Stetler-Stevenson GW: Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biohem 218:325-329, 1994
25. Kuerbitz SJ, Plunkett BS, Walsh WV. Kastan MB: Wild-type P53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 89:7491-7495, 1992
26. Lane DP: p53, the guardian of the genome, Nature (London) 358:15-16, 1992
27. Lane DP, Benchimol S: P53: oncogene or antioncogene? Genes Dev 4:1-8, 1990
28. Leeson-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ: Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 6:395-105, 1995
29. Legha SS: The role of Interferon alpha in the treatment of metastatic melanoma. Semin Oncol 24:5424-5431, 1997
30. Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J, Epstein CB: The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a 'gain of function' phenotype. Ann NY Acad Sci 768:111-128, 1995
31. Levy AT, Cioce V, Sabel ME, Garbisa 5, Grigioni WF, Liotta LA, Stetler-Stevenson WG: Increased expression of the Mr 72,000 type IV collagenase in human colonie adenocarcinoma. Cancer Res 51:439-444, 1991
32. Li J, Hu SX, Perng GS, et al: Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro. Oncogene 13:2379-2386, 1996
33. Li R, Sutphin PD, Schwartz D, et al: Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 16:3269-3277, 1998
34. Livingstone L, White A, SprouseJ, Livanos E, Jacks T, Tisty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992
35. Lübbe J, Reichel M, Burg G, Kleihues P: Absence of p53 gene mutations in cutaneous melanoma. J Invest Dematol 102:819-821, 1994
36. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M: Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 151:1105-1113, 1997
37. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992
38. Mukhopadhyay T, Roth JA: Functional inactivation of p53 by antisense RNA induces invasive ability of lung carcinoma cells and downregulates cytokeratin synthesis. Anticancer Res 16:1683-1689, 1996
39. Ozdemir E, Kakehi Y, Okuno H, Habuchi T, Okada Y, Yoshida O: Strong correlation of basement membrane degradation with p53 inactivation and/or mdm2 overexpression in superficial urothelial carcinomas. J Urol 158:206-211, 1997
40. Perry ME, Levine AJ: Tumor-suppressor p53 and the cell cycle. Curr Opin Genet Dev 3:50-54, 1993
41. Ray JM, Stetler-Stevenson WG: The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7:2062-2072, 1994
42. Ray JM, Stetler-Stevenson WG: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 14:908-917, 1995
43. Riccioni T, Cirielli C, Wang X, Passaniti A, Capogrossi MC: Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo. Gene Ther 5:747-754, 1998
44. Rigel DS, Friedman RJ, Kopf AW: The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 34:839-847, 1996
45. Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 2:985-981, 1996
46. Roth JA, Swisher SG, Merrit JA, et al: Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 25 (3, Suppl. 8):33-37, 1998
47. Schuler M, Rochlitz C, Horowitz JA, et al: A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 9:2075-2082, 1998
48. Swisher SG, Roth JA, Nemunaitis J, et al: Adenovirus-mediated gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91:763-771, 1999
49. Ueba T, Nosaka T, Takahashi JA, et al: Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and heparocellular carcinoma cells. Pror Natl Acad Sci USA 91:9009-9013, 1994
50. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T: Matrix-metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumor progression and may have prognostic value. J Pathol 180:283-289, 1996
51. van Golen KL, Risin S, Staroselsky A, Berger D, Tainsky MA, Pathak S, Price JE: Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones. Clin Exp Met 14:95-106, 1996
52. Van Meir E, Polverini PJ, Chazin VR, Su Huang HJ, De Tribolet N, Cavence WK: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nature Genet 8:171-176, 1994
53. Wang Q, Zambetti GP, Suttle DP: Inhibition of DNA topoisomerase IIa gene expression by the p53 tumor suppressor. Mol Cell Biol 17:389-397, 1997
54. Weiss J, Heine M, Arden KC, Korner B, Pilch H, Herbst RA, Jung EG: Mutation and expression of TP53 in malignant melanomas. Recent Result Cancer Res 139:137-154, 1995
55. Yang C, Cirielli C, Capogrossi MC, Passaniti A: Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55:4210-4213, 1995
56. Yin Y, Tainsky MA, Bischoff ZF, Strong IC, Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948, 1992
57. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347, 1991
58. Zhang W, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA: Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Human Gene Ther 6:155-164, 1995